▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Dec 27, 2014 by Todd Campbell

How 3 Stocks Turned $30,000 Into $1 Million

Investing $10,000 each into Regeneron, Illumina, and Alexion in 2005 would have produced $1.1 million by today.

Dec 26, 2014 by Todd Campbell

3 Investing Resolutions Worth Keeping

One Motley Fool analyst suggests three investing resolutions that could make a big impact over the long haul.

Dec 23, 2014 by Todd Campbell

Walgreen Company Delivers a Prescription for Growth

Walgreen & Company reported solid revenue and sales growth last quarter.

Dec 23, 2014 by Todd Campbell

Why Achillion Pharmaceuticals Shares Collapsed by 25% Today

Achillion Pharmaceuticals reported mixed results from clinical trials that sent shares tumbling.

Dec 23, 2014 by Todd Campbell

Biotech Stocks Are Falling: 3 Top Stocks to Buy

Gilead Sciences, Celgene Corp, and Biogen Idec may offer investors long-term opportunity.

Dec 23, 2014 by Todd Campbell

Express Scripts Hates Gilead Sciences, Loves AbbVie

Express Scripts ditches Gilead Sciences' hepatitis C treatments from its drug formulary in favor of AbbVie.

Dec 23, 2014 by Todd Campbell

Gilead Sciences Vs. AbbVie: Surprise! Sovaldi Still Matters

Gilead Sciences' Sovaldi remains the go-to cure for non-genotype 1 hepatitis C patients.

Dec 23, 2014 by Todd Campbell

This May Be the Fastest-Growing Big Pharma Next Year (Hint: It Isn't Johnson & Johnson)

Novo Nordisk is expected to increase sales faster than Johnson & Johnson in 2015.

Dec 22, 2014 by Todd Campbell

Why Gilead Sciences Shares Tumbled Today

Gilead Sciences shares fell sharply on concerns that competition from AbbVie's hepatitis C drug puts its market share at risk.

Dec 22, 2014 by Todd Campbell

Can You Guess the Best-Performing Biotech IPO of 2014? (Hint: Shares Rallied 217%)

This cancer immunotherapy treatment company's shares have soared following its IPO in June.

Dec 21, 2014 by Todd Campbell

3 Large Cap Biotech Stocks That Could Surprise Investors in 2015

Celgene Corp, Biogen Idec, and Medivation Inc. offer catalysts that could allow them to outpace estimates next year.

Dec 21, 2014 by Todd Campbell

The Average American Has This Much Credit Card Debt. How Do You Compare?

The majority of Americans carry balances on their credit cards that exceed 40% of their total credit limit.

Dec 21, 2014 by Todd Campbell

These Biotech Stocks Are Growing Even Faster Than Gilead Sciences

Medivation Inc. and Pharmacyclics are posting even faster revenue growth than Gilead Sciences.

Dec 21, 2014 by Todd Campbell

Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way

GlaxoSmithKline plc has reported impressive late stage trial results for its shingles vaccine.

Dec 20, 2014 by Todd Campbell

Top Pharmaceutical Stocks to Buy for 2015

Three fast-growing pharmaceutical stocks that investors may want to consider owning in 2015.

Dec 19, 2014 by Todd Campbell

The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?

In this week's Industry Focus, our analysts discuss their favorites of the successful 2014 healthcare large-cap stocks.

Dec 18, 2014 by Todd Campbell

Rite Aid Corporation Delivers A Huge Win

Rite Aid's fiscal third quarter earnings growth prompted the company to increase its full year earnings outlook.

Dec 17, 2014 by Todd Campbell

Pfizer, Inc. Invests in Growth... Literally

Pfizer, Inc. pays $275 million upfront for commercialization rights to Opko Health Inc.'s promising human growth hormone drug.

Dec 16, 2014 by Todd Campbell

Top Healthcare Stocks to Buy for 2015

Our Foolish insight into five healthcare stocks that could head higher next year.

Dec 15, 2014 by Todd Campbell

3 Stocks To Buy in a Market Crash

Johnson & Johnson, Celgene Corp, and Edwards Lifesciences Corp. may be good investments if markets stumble.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services